Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

SAN FRANCISCO, CA and TOKYO--(Marketwire - Sep 30, 2012) - Medivation Inc. (MDVN) and Astellas Pharma Inc. (TSE: 4503) announced that new data for enzalutamide (XTANDI ® capsules), an oral ...

NEW YORK and TOKYO, May 29, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, P ...

Xtandi will outcompete Zytiga in the pre-chemo CRPC setting. The major, imminent, question for MDVN is whether Xtandi can outcompete Zytiga in the pre-chemo setting.

Xtandi's oncology prescriptions grew annually by ~40% in fiscal 2015. Similarly, the drug's overall treatment duration over past three years has grown significantly.

The approval of the application, which was granted FDA Priority Review designation, Fast Track designation, and Real-time Oncology Review, makes Xtandi the first and only androgen receptor signaling ...

By weight, Xtandi is 65 times more expensive than gold. In the United States, that is 2.5 times the annual per capita income. In India, the name-brand drug costs more than 38 times the per capita ...

With this approval, XTANDI is now the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant ...